A preclinical study on esophageal cancer showed that CAFs may block the infiltration of CD8+ T cells and increase the infiltration of CD4+ Treg through IL-6, and targeting CAFs can improve the existing tumor immunity and enhance the efficacy of conventional immunotherapy (41). This evidence concerns the gene IL6 and esophageal cancer.